Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Thoracic 2NET 2Genitourinary 2Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Breast Neoplasms 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Melanoma 5Glioblastoma 5Carcinoma, Transitional Cell 5Ovarian Neoplasms 4Advanced Solid Tumor 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Liver Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Solid Cancer 2Small Cell Lung Cancer Extensive Stage 2Recurrence 2Neuroendocrine Tumors 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

atezolizumab 3Etoposide 2Cisplatin 2veliparib 1tivozanib 1surufatinib 1repotrectinib 1pralsetinib 1pembrolizumab 1durvalumab 1berzosertib 1avelumab 1Topotecan 1Podophyllotoxin 1Platinum 1Paclitaxel 1Nivolumab 1Ipilimumab 1Everolimus 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Neuroendocrine × atezolizumab × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting
203 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡